Terapevticheskii arkhivTerapevticheskii arkhiv0040-36602309-5342LLC Obyedinennaya Redaktsiya7635510.26442/00403660.2021.07.200931Review ArticleExtracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case reportShchekinaAntonina E.shekina_ae@mail.ruhttps://orcid.org/0000-0002-7916-2322GalstyanGennadii M.shekina_ae@mail.ruhttps://orcid.org/0000-0001-8818-8949GavrilinaOlga A.shekina_ae@mail.ruhttps://orcid.org/0000-0002-9969-8482ArapovaNatalia M.shekina_ae@mail.ruhttps://orcid.org/0000-0002-6026-5989BronyakinaSvetlana Iu.shekina_ae@mail.ruhttps://orcid.org/0000-0003-1492-1735KotovaEkaterina S.shekina_ae@mail.ruhttps://orcid.org/0000-0002-7968-1923TroitskayaVera V.shekina_ae@mail.ruhttps://orcid.org/0000-0002-4827-8947ParovichnikovaElena N.shekina_ae@mail.ruhttps://orcid.org/0000-0001-6177-3566MaschanMikhail A.shekina_ae@mail.ruhttps://orcid.org/0000-0003-1735-0093SavchenkoValerii G.shekina_ae@mail.ruhttps://orcid.org/0000-0001-8188-5557National Research Center for HematologyDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology150720219378118172107202121072021Copyright © 2021, Consilium Medicum2021<p>Сytokine release syndrome is the common complication of CAR-T therapy. We report a case of patient with B-cell acute lymphoblastic leukemia developing сytokine release syndrome with shock and multiple organ failure and requiring cytokine removal and hemodiafiltration. Remission of the disease was achieved after CAR-T therapy.</p>CAR-T-cell therapycytokine release syndromecytokine adsorptionCAR-T-терапиясиндром высвобождения цитокиновсорбция цитокинов[June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-5. DOI:10.1126/science.aar6711][Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-48. DOI:10.1056/nejmoa1709866][Gutierrefz C, Brown ART, Herr MM, et al. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. J Crit Care. 2020;58:58-64. DOI:10.1016/j.jcrc.2020.04.008][Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood and Marrow Transplant. 2019;25(4):625-38. DOI:10.1016/j.bbmt.2018.12.758][Si S, Teachey DT. Spotlight on tocilizumab in the treatment of car-t-cell-induced cytokine release syndrome. Ther Clin Risk Manag. 2020;16:705-14. DOI:10.2147/TCRM.S223468][Bottari G, Merli P, Guzzo I, et al. Multimodal Therapeutic Approach of Cytokine Release Syndrome Developing in a Child Given Chimeric Antigen Receptor-Modified T Cell Infusion. Crit Care Explor. 2020;2(1):e0071. DOI:10.1097/cce.0000000000000071][Stahl K, Schmidt BMW, Hoeper MM, et al. Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome. J Crit Care. 2020;57:124-9. DOI:10.1016/j.jcrc.2020.02.010][Schädler D, Pausch C, Heise D, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial. Plos ONE. 2017;12(10):e018715. DOI:10.1371/journal.pone.0187015][Magomedov MA, Kim TG, Masolitin SV, et al. Use of sorbent based on hypercrosslinked styrene-divinylbenzene copolymer with immobilized LPS-selective ligand in hemoperfusion for treatment of patients with septic shock. Obshchaya Reanimatologiya. 2021;16(6):31-53. DOI:10.15360/1813-9779-2020-6-31-53][Bernardi MH, Rinoesl H, Dragosits K, et al. Effect of hemoadsorption during cardiopulmonary bypass surgery – a blinded, randomized, controlled pilot study using a novel adsorbent. Crit Care. 2016;20(1):96. DOI:10.1186/s13054-016-1270-0][Al Shareef K, Bakouri M. Cytokine Blood Filtration Responses in COVID-19. Blood Purif. 2020;50(2):141-9. DOI:10.1159/000508278][Azoulay E, Shimabukuro-Vornhagen A, Darmon M, et al. Critical care management of chimeric antigen receptor T cell-related toxicity be aware and prepared. Am J Respir Crit Care Med. 2019;200(1):20-3. DOI:10.1164/rccm.201810-1945ED][Azoulay E, Castro P, Maamar A, et al. Critical Care Management of CAR-T Cell Recipients: The CARTTAS International Study. Lancet Haematol. 2021;8(5):e355-64. DOI:10.1016/S2352-3026(21)00060-0][Gutierrez C, McEvoy C, Mead E, et al. Management of the critically ill adult chimeric antigen receptor-t cell therapy patient: A critical care perspective. Crit Care Med. 2018;46(9):1402-10. DOI:10.1097/CCM.0000000000003258][Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531-44. DOI:10.1056/NEJMoa1707447][Dai H, Wu Z, Jia H, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):30. DOI:10.1186/s13045-020-00856-8][Gupta S, Seethapathy H, Strohbehn IA, et al. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. Am J Kidney Dis. 2020;76(1):63-71. DOI:10.1053/j.ajkd.2019.10.011][Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra45. DOI:10.1126/scitranslmed.3008226][Liu S, Deng B, Yin Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 2020;10(2):15. DOI:10.1038/s41408-020-0280-y][Ankawi G, Xie Y, Yang B, et al. What Have We Learned about the Use of Cytosorb Adsorption Columns? Blood Purif. 2019;48(3):196-202. DOI:10.1159/000500013][Kogelmann K, Jarczak D, Scheller M, et al. Hemoadsorption by CytoSorb in septic patients: A case series. Crit Care. 2017;21(1):74. DOI:10.1186/s13054-017-1662-9]